State Board of Administration of Florida Retirement System decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) by 1.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,430 shares of the medical research company's stock after selling 1,246 shares during the quarter. State Board of Administration of Florida Retirement System owned about 0.11% of Natera worth $4,330,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its holdings in shares of Natera by 6.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 2,904 shares of the medical research company's stock worth $271,000 after purchasing an additional 166 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Natera by 43.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,303 shares of the medical research company's stock worth $1,056,000 after acquiring an additional 3,417 shares during the last quarter. Fifth Third Bancorp raised its holdings in shares of Natera by 6.3% during the fourth quarter. Fifth Third Bancorp now owns 5,285 shares of the medical research company's stock valued at $494,000 after acquiring an additional 313 shares in the last quarter. Duality Advisers LP purchased a new position in Natera during the 4th quarter valued at $613,000. Finally, Arizona State Retirement System lifted its position in shares of Natera by 5.4% in the 4th quarter. Arizona State Retirement System now owns 22,717 shares of the medical research company's stock worth $2,122,000 after purchasing an additional 1,157 shares during the period. Hedge funds and other institutional investors own 96.24% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Cowen lowered their price target on shares of Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Piper Sandler lowered their target price on Natera from $75.00 to $60.00 and set a "na" rating on the stock in a report on Sunday, May 15th. Robert W. Baird cut their price target on Natera from $100.00 to $71.00 in a research note on Friday, May 6th. Cowen cut their price objective on shares of Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Finally, Stephens started coverage on shares of Natera in a report on Monday, April 25th. They set an "overweight" rating and a $54.00 price target on the stock. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and a consensus price target of $93.18.

Insider Activity at Natera

Natera Price Performance

NTRA stock opened at $53.59 on Friday. The stock has a market cap of $5.20 billion, a PE ratio of -8.84 and a beta of 1.33. Natera, Inc. has a 12 month low of $26.10 and a 12 month high of $129.09. The company has a 50-day moving average price of $41.43 and a 200 day moving average price of $45.16. The company has a current ratio of 3.58, a quick ratio of 4.13 and a debt-to-equity ratio of 0.63.

Natera (NASDAQ:NTRA – Get Rating) last announced its earnings results on Thursday, August 4th. The medical research company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.03). The business had revenue of $198.20 million for the quarter, compared to analysts' expectations of $193.67 million. Natera had a negative net margin of 79.57% and a negative return on equity of 95.97%. The firm's quarterly revenue was up 39.6% on a year-over-year basis. During the same quarter last year, the firm earned ($1.32) EPS. Equities research analysts anticipate that Natera, Inc. will post -5.75 earnings per share for the current year.

Natera Company Profile

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also

• Get a free copy of the StockNews.com research report on Natera (NTRA)
• Look at Honeywell for a Steady and Diversified Stock
• Why Invest in High-Yield Dividend Stocks?
• Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
• Find and Profitably Trade Stocks at 52-Week Lows
• Solar Stocks Shine Brightly After Passage Of Clean Energy Bill

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.